

Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Growth (Status and Outlook) 2023-2029

<https://marketpublishers.com/r/G8CB62382FF0EN.html>

Date: March 2023

Pages: 101

Price: US\$ 3,660.00 (Single User License)

ID: G8CB62382FF0EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

AAV is transformed from a naturally occurring virus into a delivery mechanism for gene therapy. The viral DNA is replaced with new DNA, and it becomes a precisely coded vector and is no longer considered a virus, as most of the viral components have been replaced. The AAV Vector-Based Gene Therapy market size is anticipated to shoot up exponentially attributing to an increase in the approval of a growing number of gene therapies and readily adoption on approval, ability to treat a broad array of conditions, increasing prevalence of diseases, convenient one-time dosing approach and curative treatment options.

LPI (LP Information)' newest research report, the "Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Industry Forecast" looks at past sales and reviews total world Adeno-Associated Virus (AAV) Vector-Based Gene Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Adeno-Associated Virus (AAV) Vector-Based Gene Therapy sales for 2023 through 2029. With Adeno-Associated Virus (AAV) Vector-Based Gene Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Adeno-Associated Virus (AAV) Vector-Based Gene Therapy industry.

This Insight Report provides a comprehensive analysis of the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading

global companies with a focus on Adeno-Associated Virus (AAV) Vector-Based Gene Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Adeno-Associated Virus (AAV) Vector-Based Gene Therapy and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy.

The global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Adeno-Associated Virus (AAV) Vector-Based Gene Therapy is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Adeno-Associated Virus (AAV) Vector-Based Gene Therapy is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Adeno-Associated Virus (AAV) Vector-Based Gene Therapy is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Adeno-Associated Virus (AAV) Vector-Based Gene Therapy players cover BioMarin Pharmaceutical, Sangamo Therapeutics, Amicus Therapeutics, Roche, Pfizer, NightstaRx, MeiraGTx, Sarepta Therapeutics and Neurocrine Biosciences, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type

Single-stranded AAV (ssAAV)

Self-complementary AAV (scAAV)

Segmentation by application

Hemophilia

Ophthalmology

Lysosomal Storage Disorders

Neurological Disorders

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

BioMarin Pharmaceutical

Sangamo Therapeutics

Amicus Therapeutics

Roche

Pfizer

NightstaRx

MeiraGTx

Sarepta Therapeutics

Neurocrine Biosciences

Voyager Therapeutics

Asklepios Biopharmaceutical

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

2.1.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2018-2029

2.1.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size CAGR by Region 2018 VS 2022 VS 2029

2.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Segment by Type

2.2.1 Single-stranded AAV (ssAAV)

2.2.2 Self-complementary AAV (scAAV)

2.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type

2.3.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size CAGR by Type (2018 VS 2022 VS 2029)

2.3.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2018-2023)

2.4 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Segment by Application

2.4.1 Hemophilia

2.4.2 Ophthalmology

2.4.3 Lysosomal Storage Disorders

2.4.4 Neurological Disorders

2.4.5 Others

2.5 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application

2.5.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size CAGR by Application (2018 VS 2022 VS 2029)

2.5.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application (2018-2023)

3 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET SIZE BY PLAYER

3.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Players

3.1.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Players (2018-2023)

3.1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Players (2018-2023)

3.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY BY REGIONS

4.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Regions (2018-2023)

4.2 Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth (2018-2023)

4.3 APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth (2018-2023)

4.4 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth (2018-2023)

4.5 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth (2018-2023)

5 AMERICAS

5.1 Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023)

5.2 Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size

by Type (2018-2023)

5.3 Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size

by Application (2018-2023)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2018-2023)

6.2 APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023)

6.3 APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023)

6.4 China

6.5 Japan

6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 EUROPE

7.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Country (2018-2023)

7.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023)

7.3 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Region (2018-2023)

8.2 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023)

8.3 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 GLOBAL ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET FORECAST

10.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Regions (2024-2029)

10.1.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Regions (2024-2029)

10.1.2 Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast

10.1.3 APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast

10.1.4 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast

10.1.5 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast

10.2 Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Country (2024-2029)

10.2.1 United States Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.2.2 Canada Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.2.3 Mexico Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.2.4 Brazil Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market

Forecast

10.3 APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Region (2024-2029)

10.3.1 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.3.2 Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.3.3 Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.3.4 Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.3.5 India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.3.6 Australia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.4 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Country (2024-2029)

10.4.1 Germany Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.4.2 France Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.4.3 UK Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.4.4 Italy Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.4.5 Russia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.5 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Region (2024-2029)

10.5.1 Egypt Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.5.2 South Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.5.3 Israel Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.5.4 Turkey Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.5.5 GCC Countries Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.6 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Type (2024-2029)

10.7 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Application (2024-2029)

11 KEY PLAYERS ANALYSIS

11.1 BioMarin Pharmaceutical

11.1.1 BioMarin Pharmaceutical Company Information

11.1.2 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

11.1.3 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)

11.1.4 BioMarin Pharmaceutical Main Business Overview

11.1.5 BioMarin Pharmaceutical Latest Developments

11.2 Sangamo Therapeutics

11.2.1 Sangamo Therapeutics Company Information

11.2.2 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

11.2.3 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)

11.2.4 Sangamo Therapeutics Main Business Overview

11.2.5 Sangamo Therapeutics Latest Developments

11.3 Amicus Therapeutics

11.3.1 Amicus Therapeutics Company Information

11.3.2 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

11.3.3 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)

11.3.4 Amicus Therapeutics Main Business Overview

11.3.5 Amicus Therapeutics Latest Developments

11.4 Roche

11.4.1 Roche Company Information

11.4.2 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

11.4.3 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)

11.4.4 Roche Main Business Overview

11.4.5 Roche Latest Developments

11.5 Pfizer

11.5.1 Pfizer Company Information

11.5.2 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

11.5.3 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)

11.5.4 Pfizer Main Business Overview

11.5.5 Pfizer Latest Developments

11.6 NightstaRx

11.6.1 NightstaRx Company Information

11.6.2 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

11.6.3 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)

11.6.4 NightstaRx Main Business Overview

11.6.5 NightstaRx Latest Developments

11.7 MeiraGTx

11.7.1 MeiraGTx Company Information

11.7.2 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

11.7.3 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)

11.7.4 MeiraGTx Main Business Overview

11.7.5 MeiraGTx Latest Developments

11.8 Sarepta Therapeutics

11.8.1 Sarepta Therapeutics Company Information

11.8.2 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

11.8.3 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)

11.8.4 Sarepta Therapeutics Main Business Overview

11.8.5 Sarepta Therapeutics Latest Developments

11.9 Neurocrine Biosciences

11.9.1 Neurocrine Biosciences Company Information

11.9.2 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

11.9.3 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)

11.9.4 Neurocrine Biosciences Main Business Overview

- 11.9.5 Neurocrine Biosciences Latest Developments
- 11.10 Voyager Therapeutics
 - 11.10.1 Voyager Therapeutics Company Information
 - 11.10.2 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
 - 11.10.3 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
 - 11.10.4 Voyager Therapeutics Main Business Overview
 - 11.10.5 Voyager Therapeutics Latest Developments
- 11.11 Asklepios Biopharmaceutical
 - 11.11.1 Asklepios Biopharmaceutical Company Information
 - 11.11.2 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
 - 11.11.3 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
 - 11.11.4 Asklepios Biopharmaceutical Main Business Overview
 - 11.11.5 Asklepios Biopharmaceutical Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size CAGR by Region (2018 VS 2022 VS 2029) & (\$ Millions)

Table 2. Major Players of Single-stranded AAV (ssAAV)

Table 3. Major Players of Self-complementary AAV (scAAV)

Table 4. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size CAGR by Type (2018 VS 2022 VS 2029) & (\$ Millions)

Table 5. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023) & (\$ Millions)

Table 6. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2018-2023)

Table 7. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size CAGR by Application (2018 VS 2022 VS 2029) & (\$ Millions)

Table 8. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023) & (\$ Millions)

Table 9. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application (2018-2023)

Table 10. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Players (2018-2023) & (\$ Millions)

Table 11. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Player (2018-2023)

Table 12. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Key Players Head office and Products Offered

Table 13. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)

Table 14. New Products and Potential Entrants

Table 15. Mergers & Acquisitions, Expansion

Table 16. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Regions 2018-2023 & (\$ Millions)

Table 17. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Regions (2018-2023)

Table 18. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Country/Region (2018-2023) & (\$ millions)

Table 19. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Country/Region (2018-2023)

Table 20. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market

Size by Country (2018-2023) & (\$ Millions)

Table 21. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Country (2018-2023)

Table 22. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023) & (\$ Millions)

Table 23. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2018-2023)

Table 24. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023) & (\$ Millions)

Table 25. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application (2018-2023)

Table 26. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2018-2023) & (\$ Millions)

Table 27. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Region (2018-2023)

Table 28. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023) & (\$ Millions)

Table 29. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2018-2023)

Table 30. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023) & (\$ Millions)

Table 31. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application (2018-2023)

Table 32. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023) & (\$ Millions)

Table 33. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Country (2018-2023)

Table 34. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023) & (\$ Millions)

Table 35. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2018-2023)

Table 36. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023) & (\$ Millions)

Table 37. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application (2018-2023)

Table 38. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2018-2023) & (\$ Millions)

Table 39. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Region (2018-2023)

Table 40. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023) & (\$ Millions)

Table 41. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2018-2023)

Table 42. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023) & (\$ Millions)

Table 43. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application (2018-2023)

Table 44. Key Market Drivers & Growth Opportunities of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy

Table 45. Key Market Challenges & Risks of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy

Table 46. Key Industry Trends of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy

Table 47. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Regions (2024-2029) & (\$ Millions)

Table 48. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share Forecast by Regions (2024-2029)

Table 49. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Type (2024-2029) & (\$ Millions)

Table 50. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Application (2024-2029) & (\$ Millions)

Table 51. BioMarin Pharmaceutical Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors

Table 52. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

Table 53. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 54. BioMarin Pharmaceutical Main Business

Table 55. BioMarin Pharmaceutical Latest Developments

Table 56. Sangamo Therapeutics Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors

Table 57. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

Table 58. Sangamo Therapeutics Main Business

Table 59. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 60. Sangamo Therapeutics Latest Developments

Table 61. Amicus Therapeutics Details, Company Type, Adeno-Associated Virus (AAV)

Vector-Based Gene Therapy Area Served and Its Competitors

Table 62. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

Table 63. Amicus Therapeutics Main Business

Table 64. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 65. Amicus Therapeutics Latest Developments

Table 66. Roche Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors

Table 67. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

Table 68. Roche Main Business

Table 69. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 70. Roche Latest Developments

Table 71. Pfizer Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors

Table 72. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

Table 73. Pfizer Main Business

Table 74. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 75. Pfizer Latest Developments

Table 76. NightstaRx Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors

Table 77. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

Table 78. NightstaRx Main Business

Table 79. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 80. NightstaRx Latest Developments

Table 81. MeiraGTx Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors

Table 82. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

Table 83. MeiraGTx Main Business

Table 84. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 85. MeiraGTx Latest Developments

Table 86. Sarepta Therapeutics Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors

Table 87. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

Table 88. Sarepta Therapeutics Main Business

Table 89. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 90. Sarepta Therapeutics Latest Developments

Table 91. Neurocrine Biosciences Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors

Table 92. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

Table 93. Neurocrine Biosciences Main Business

Table 94. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 95. Neurocrine Biosciences Latest Developments

Table 96. Voyager Therapeutics Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors

Table 97. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

Table 98. Voyager Therapeutics Main Business

Table 99. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 100. Voyager Therapeutics Latest Developments

Table 101. Asklepios Biopharmaceutical Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors

Table 102. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

Table 103. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 104. Asklepios Biopharmaceutical Main Business

Table 105. Asklepios Biopharmaceutical Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Report Years Considered
- Figure 2. Research Objectives
- Figure 3. Research Methodology
- Figure 4. Research Process and Data Source
- Figure 5. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate 2018-2029 (\$ Millions)
- Figure 6. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Geographic Region (2018, 2022 & 2029) & (\$ millions)
- Figure 7. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Country/Region (2022)
- Figure 8. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Country/Region (2018, 2022 & 2029)
- Figure 9. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type in 2022
- Figure 10. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in Hemophilia
- Figure 11. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Hemophilia (2018-2023) & (\$ Millions)
- Figure 12. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in Ophthalmology
- Figure 13. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Ophthalmology (2018-2023) & (\$ Millions)
- Figure 14. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in Lysosomal Storage Disorders
- Figure 15. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Lysosomal Storage Disorders (2018-2023) & (\$ Millions)
- Figure 16. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in Neurological Disorders
- Figure 17. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Neurological Disorders (2018-2023) & (\$ Millions)
- Figure 18. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in Others
- Figure 19. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Others (2018-2023) & (\$ Millions)
- Figure 20. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application in 2022

Figure 21. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Player in 2022

Figure 22. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Regions (2018-2023)

Figure 23. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2018-2023 (\$ Millions)

Figure 24. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2018-2023 (\$ Millions)

Figure 25. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2018-2023 (\$ Millions)

Figure 26. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2018-2023 (\$ Millions)

Figure 27. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Value Market Share by Country in 2022

Figure 28. United States Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2018-2023 (\$ Millions)

Figure 29. Canada Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2018-2023 (\$ Millions)

Figure 30. Mexico Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2018-2023 (\$ Millions)

Figure 31. Brazil Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2018-2023 (\$ Millions)

Figure 32. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Region in 2022

Figure 33. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type in 2022

Figure 34. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application in 2022

Figure 35. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2018-2023 (\$ Millions)

Figure 36. Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2018-2023 (\$ Millions)

Figure 37. Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2018-2023 (\$ Millions)

Figure 38. Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2018-2023 (\$ Millions)

Figure 39. India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2018-2023 (\$ Millions)

Figure 40. Australia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market

Size Growth 2018-2023 (\$ Millions)

Figure 41. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Country in 2022

Figure 42. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2018-2023)

Figure 43. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application (2018-2023)

Figure 44. Germany Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2018-2023 (\$ Millions)

Figure 45. France Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2018-2023 (\$ Millions)

Figure 46. UK Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2018-2023 (\$ Millions)

Figure 47. Italy Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2018-2023 (\$ Millions)

Figure 48. Russia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2018-2023 (\$ Millions)

Figure 49. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Region (2018-2023)

Figure 50. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2018-2023)

Figure 51. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application (2018-2023)

Figure 52. Egypt Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2018-2023 (\$ Millions)

Figure 53. South Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2018-2023 (\$ Millions)

Figure 54. Israel Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2018-2023 (\$ Millions)

Figure 55. Turkey Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2018-2023 (\$ Millions)

Figure 56. GCC Country Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2018-2023 (\$ Millions)

Figure 57. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2024-2029 (\$ Millions)

Figure 58. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2024-2029 (\$ Millions)

Figure 59. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2024-2029 (\$ Millions)

Figure 60. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2024-2029 (\$ Millions)

Figure 61. United States Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2024-2029 (\$ Millions)

Figure 62. Canada Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2024-2029 (\$ Millions)

Figure 63. Mexico Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2024-2029 (\$ Millions)

Figure 64. Brazil Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2024-2029 (\$ Millions)

Figure 65. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2024-2029 (\$ Millions)

Figure 66. Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2024-2029 (\$ Millions)

Figure 67. Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2024-2029 (\$ Millions)

Figure 68. Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2024-2029 (\$ Millions)

Figure 69. India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2024-2029 (\$ Millions)

Figure 70. Australia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2024-2029 (\$ Millions)

Figure 71. Germany Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2024-2029 (\$ Millions)

Figure 72. France Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2024-2029 (\$ Millions)

Figure 73. UK Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2024-2029 (\$ Millions)

Figure 74. Italy Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2024-2029 (\$ Millions)

Figure 75. Russia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2024-2029 (\$ Millions)

Figure 76. Spain Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2024-2029 (\$ Millions)

Figure 77. Egypt Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2024-2029 (\$ Millions)

Figure 78. South Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2024-2029 (\$ Millions)

Figure 79. Israel Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market

Size 2024-2029 (\$ Millions)

Figure 80. Turkey Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market

Size 2024-2029 (\$ Millions)

Figure 81. GCC Countries Adeno-Associated Virus (AAV) Vector-Based Gene Therapy

Market Size 2024-2029 (\$ Millions)

Figure 82. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market

Size Market Share Forecast by Type (2024-2029)

Figure 83. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market

Size Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Growth (Status and Outlook) 2023-2029

Product link: <https://marketpublishers.com/r/G8CB62382FF0EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G8CB62382FF0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

